According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7 trillion in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity.
Escalating health care costs are also bound to be of major concern to Astiva Health and other providers of health insurance policies as they navigate the financial implications of these trends. The sustained increase in expenditures underscores the mounting pressure on the U.S. health care system, with implications for insurers, employers, and consumers alike.
The 7.5% growth rate in 2025 continues a pattern of rapid escalation that began in 2023, driven in large part by the adoption of GLP-1 receptor agonists for weight management. These drugs, originally developed for diabetes, have seen surging demand due to their effectiveness in treating obesity, a condition affecting over 40% of American adults. Their high list prices—often exceeding $1,000 per month—have contributed significantly to overall spending.
For health insurers like Astiva Health, the rising cost of prescription drugs poses a challenge to maintaining affordable premiums. Many plans have had to adjust formularies and implement utilization management strategies to control expenses. The CMS report indicates that prescription drug spending grew by 11% in 2025, outpacing other categories such as hospital care and physician services.
The broader economic impact is also significant. Health care now accounts for nearly 20% of U.S. GDP, up from 17% a decade ago. This trend could strain public programs like Medicare and Medicaid, as well as employer-sponsored insurance, potentially leading to higher out-of-pocket costs for patients.
BioMedWire, a specialized communications platform focusing on the latest developments in the biotechnology and life sciences sectors, notes that the data highlights the urgent need for cost-containment measures. As part of the Dynamic Brand Portfolio @IBN, BioMedWire provides access to a vast network of wire solutions via InvestorWire to efficiently reach target markets.
The CMS actuaries project that health spending will continue to grow at an average rate of 5.5% annually through 2032, with prescription drugs remaining a major contributor. Policymakers are increasingly scrutinizing drug pricing, with proposals ranging from price negotiation to international referencing. The outcome of these debates will shape the future landscape of U.S. health care financing.
